Dr. Reddy's Laboratories Limited — Investor Meet, 27-01-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Dr. Reddy's Q3FY26 revenue hit ₹8,727 Cr (+4.4% YoY), driven by strong base business growth (ex-Lenalidomide) and favorable forex, despite generic pricing pressure. Underlying EBITDA margin was 24.8% (adjusted for a one-time ₹117 Cr provision). PAT came in at ₹1,210 Cr. India business grew 19% (17-18% organic), expected to be 15%+ sustainable. Semaglutide for diabetes is approved in India, with Canada approval anticipated Feb-May. Abatacept IV filing done in the US, Europe launch eyed for July 2027. US biosimilar launches for Denosumab and Rituximab face regulatory delays. Management is focused on pipeline progress and cost control.